We are live on ! Find out more
DYN icon

Dyne Therapeutics

200 hedge funds and large institutions have $2.63B invested in Dyne Therapeutics in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 68 increasing their positions, 63 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 34

8% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 63

0% more funds holding

Funds holding: 200200 (0)

2.29% less ownership

Funds ownership: 111.98%109.69% (-2.3%)

30% less funds holding in top 10

Funds holding in top 10: 107 (-3)

35% less capital invested

Capital invested by funds: $4.03B → $2.63B (-$1.4B)

65% less call options, than puts

Call options by funds: $3.57M | Put options by funds: $10.3M

Holders
200
Holders Change
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
7
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-30%
% of All Funds
0.09%
New
38
Increased
68
Reduced
63
Closed
34
Calls
$3.57M
Puts
$10.3M
Net Calls
-$6.72M
Net Calls Change
-$8.69M
Name Holding Trade Value Shares
Change
Change in
Stake
WA
51
Wasatch Advisors
Utah
$7.55M -$103K -3,473 -1%
Ensign Peak Advisors
52
Ensign Peak Advisors
Utah
$7.44M +$84.3K +2,850 +0.9%
FCM
53
Frontier Capital Management
Massachusetts
$7.02M +$8.82M +298,052 New
Qube Research & Technologies (QRT)
54
Qube Research & Technologies (QRT)
United Kingdom
$6.3M +$7.22M +244,211 +1,054%
N
55
Nuveen
North Carolina
$6.28M -$296K -10,010 -4%
VOYA Investment Management
56
VOYA Investment Management
Georgia
$5.89M -$165K -5,582 -2%
SFM
57
Sphera Funds Management
Israel
$5.57M +$5.32M +179,758 +318%
Bank of New York Mellon
58
Bank of New York Mellon
New York
$5.53M +$20.6K +698 +0.3%
RCM
59
Ratan Capital Management
Florida
$5.44M
FCM
60
Farallon Capital Management
California
$5.4M -$5.88M -198,879 -46%
Ameriprise
61
Ameriprise
Minnesota
$5.17M +$199K +6,735 +3%
Barclays
62
Barclays
United Kingdom
$4.53M -$446K -15,070 -7%
Axa
63
Axa
France
$4.44M -$8.87K -300 -0.2%
CM
64
Crestline Management
Texas
$4.35M +$1.99M +67,137 +57%
Balyasny Asset Management
65
Balyasny Asset Management
Illinois
$3.99M -$2.24M -75,804 -31%
Rafferty Asset Management
66
Rafferty Asset Management
New York
$3.95M +$74.5K +2,520 +2%
AllianceBernstein
67
AllianceBernstein
Tennessee
$3.61M -$917K -30,993 -17%
Neuberger Berman Group
68
Neuberger Berman Group
New York
$3.59M +$451K +15,240 +11%
IHAM
69
Integral Health Asset Management
New York
$3.53M +$4.44M +150,000 New
Schroder Investment Management Group
70
Schroder Investment Management Group
United Kingdom
$3.48M +$1.68M +56,961 +63%
Prudential Financial
71
Prudential Financial
New Jersey
$3.43M -$3.27M -110,400 -43%
UBS AM
72
UBS AM
Illinois
$3.38M +$267K +9,029 +7%
Citigroup
73
Citigroup
New York
$3.37M +$2.32M +78,479 +122%
D.E. Shaw & Co
74
D.E. Shaw & Co
New York
$3.15M +$1.8M +60,732 +83%
SFAM
75
Springhill Fund Asset Management
Hong Kong
$3.09M +$3.88M +131,200 New

DYN Hedge Fund Activity: Q4 2024 in Review

200 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2024, worth a combined $2.63B — down 35% from $4.03B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new DYN positions and 34 closed out — a net gain of 4 holders — while 68 added to existing stakes and 63 trimmed.

The largest buyer was Jefferies Financial Group, opening a new position worth an estimated $53.2M. The largest seller was RTW Investments, cutting an estimated $47.3M.

  • 200 institutional investors held Dyne Therapeutics (DYN) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $2.63B of Dyne Therapeutics stock for Q4 2024, down 35% quarter-over-quarter.
  • 38 funds opened new Dyne Therapeutics positions in Q4 2024 and 34 closed out, a net change of +4 holders.
  • The largest Dyne Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $53.2M added.
  • The largest Dyne Therapeutics seller in Q4 2024 was RTW Investments, an estimated $47.3M sold.

Based on aggregated 13F filings for Q4 2024.